PTSD

Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

This theoretical commentary (2018) highlights the paradigm-shifting implications of psychedelic-assisted psychotherapy in light of a triple crisis within contemporary psychiatry, concerning the lack of reliable therapeutics, a heterogeneity of diagnoses, and a reductionist understanding of mental disorders that explains away the psyche by reducing it to underlying brain processes, whereas the new paradigm aims to incorporate these dimensions in a holistic understanding of human beings and the social factors of their culture and environment.

Authors

  • Eduardo Schenberg

Published

Frontiers in Pharmacology
meta Study

Abstract

Mental disorders are rising while development of novel psychiatric medications is declining. This stall in innovation has also been linked with intense debates on the current diagnostics and explanations for mental disorders, together constituting a paradigmatic crisis. A radical innovation is psychedelic-assisted psychotherapy (PAP): professionally supervised use of ketamine, MDMA, psilocybin, LSD and ibogaine as part of elaborated psychotherapy programs. Clinical results so far have shown safety and efficacy, even for “treatment resistant” conditions, and thus deserve increasing attention from medical, psychological and psychiatric professionals. But more than novel treatments, the PAP model also has important consequences for the diagnostics and explanation axis of the psychiatric crisis, challenging the discrete nosological entities and advancing novel explanations for mental disorders and their treatment, in a model considerate of social and cultural factors, including adversities, trauma, and the therapeutic potential of some non-ordinary states of consciousness.

Available with Blossom Pro

Research Summary of 'Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development'

Introduction

Psychiatric research and development has been described as facing a paradigmatic crisis: the prevalence of mental disorders is rising while the development of novel psychiatric medications has slowed. Debates have intensified about diagnostic systems and explanatory models, with initiatives such as the Research Domain Criteria (RDoC) and network psychopathology offering dimensional, systems-based alternatives to categorical nosologies like the DSM. These debates highlight a broader explanatory impasse in psychiatry, summarised by competing claims that mental disorders are reducible to brain dysfunctions versus concerns that psychiatry is neglecting the psychological/experiential (“the psyche”). Laviola and colleagues introduce psychedelic-assisted psychotherapy (PAP) as a potential radical innovation addressing both treatment and explanatory gaps. Rather than presenting detailed new trial data, the paper reviews clinical developments with substances such as ketamine, MDMA, psilocybin, LSD and ibogaine and explores how combining potent psychoactive drugs with structured psychotherapy may alter therapeutic paradigms, diagnostic thinking and explanatory models in psychiatry. The authors frame PAP not only as a set of promising interventions but also as a model that emphasises the therapeutic role of meaningful altered states of consciousness within biopsychosocial contexts.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

  • Study Type
    meta
  • Journal
  • Topic
  • Author
  • APA Citation

    Schenberg, E. E. (2018). Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology, 9. https://doi.org/10.3389/fphar.2018.00733

References (89)

Papers cited by this study that are also in Blossom

The psychopharmacology of hallucinogens

Abraham, H. D., Aldridge, A. M., Gogia, P. · Neuropsychopharmacology (1996)

Ibogaine: a review

Alper, K. · The Alkaloids Chemistry and Biology (2001)

146 cited
Intimate insight: MDMA changes how people talk about significant others

Baggot, M. J., Kirkpatrick, M. G., Bedi, G. et al. · Journal of Psychopharmacology (2015)

53 cited
Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety

Ionescu, D. F., Vande Voort, J. L., Niciu, M. J. et al. · Journal of Psychiatric Research (2014)

Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis

Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder

Bouso, J. C., Doblin, R., Farré, M. et al. · Journal of Psychoactive Drugs (2008)

Ibogaine in the treatment of substance dependence

Brown, T. K. · Current Drug Abuse Reviews (2013)

Show all 89 references
Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

Brown, T. K., Alper, K. · The American Journal of Drug and Alcohol Abuse (2017)

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Psychedelics and connectedness

Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)

The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories

Carhart-Harris, R. L., Wall, M. B., Erritzoe, D. et al. · International Journal of Neuropsychopharmacology (2013)

90 cited
The use of ketamine as an antidepressant: a systematic review and meta-analysis

Coyle, C. M., Laws, K. R. · Human Psychopharmacology (2015)

Flashback: psychiatric experimentation with LSD in historical perspective

Dyck, E. · Canadian Journal of Psychiatry (2005)

Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder

Feder, A., Parides, M. K., Murrough, J. W. · JAMA Psychiatry (2014)

528 cited
Ketamine administration in depressive disorders: a systematic review and meta-analysis

Fond, G., Loundou, A., Macgregor, A. et al. · Psychopharmacology (2014)

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction

Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

594 cited
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision

Hendricks, P. S., Clark, B., Johnson, M. W. et al. · Journal of Psychopharmacology (2014)

89 cited
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)

345 cited
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review

Iadarola, N. D., Niciu, M. J., Richards, E. M. et al. · Therapeutic Advances in Chronic Disease (2015)

Psychedelics not linked to mental health problems or suicidal behavior: A population study.

Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers

Johnson, M. W., Sewell, R. A., Griffiths, R. R. · Drug and Alcohol Dependence (2012)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Long-term follow-up of psilocybin-facilitated smoking cessation

Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)

562 cited
Potential Therapeutic Effects of Psilocybin

Johnson, M. W., Griffiths, R. R. · Neurotherapeutics (2017)

LSD enhances the emotional response to music

Kaelen, M., Barrett, F. S., Roseman, L. et al. · Psychopharmacology (2015)

The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation

Koenig, X., Hilber, K. · Journal of Humanistic Psychology (2015)

Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers

Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)

Psychedelics and mental health: a population study

Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)

Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence

Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V. et al. · Journal of Psychoactive Drugs (2007)

154 cited
Ketamine psychedelic therapy (KPT): a review of the results of ten years of research

Krupitsky, E. M., Grinenko, A. Y. · Journal of Psychoactive Drugs (1997)

Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow

Lewis, C. R., Preller, K. H., Kraehenmann, R. et al. · NeuroImage (2017)

74 cited
Alterations of consciousness and mystical-type experiences after acute LSD in humans

Liechti, M. E., Dolder, P. C., Schmid, Y. · Psychopharmacology (2016)

190 cited
Do the dissociative side effects of ketamine mediate its antidepressant effects?

Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F. et al. · Journal of Affective Disorders (2014)

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)

Broadband Cortical Desynchronization Underlies the Human Psychedelic State

Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)

427 cited
Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

Psychedelics as Medicines: An Emerging New Paradigm

Nichols, C. D., Nichols, D. E., Johnson, M. W. · Clinical Pharmacology and Therapeutics (2016)

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Frampton, C. M., Yazar-Klosinski, B., Nollar, G. E. · The American Journal of Drug and Alcohol Abuse (2017)

122 cited
Psychedelics and the science of self-experience

Nour, M. R., Carhart-Harris, R. L. · British Journal of Psychiatry (2017)

Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)

Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)

Effects of Schedule I drug laws on neuroscience research and treatment innovation

King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)

The pharmacology of lysergic acid diethylamide: a review

Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)

Phenomenology, Structure, and Dynamic of Psychedelic States

Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Psychedelic Psychotherapy Insights From 25 Years of Research

Richards, W. A. · Journal of Humanistic Psychology (2016)

Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression

Romeo, B., Choucha, W., Fossati, P. et al. · Psychiatry Research (2015)

Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression

Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)

Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin

Schartner, M., Carhart-Harris, R. L., Barrett, A. B. et al. · Scientific Reports (2017)

19 cited
Treating drug dependence with the aid of ibogaine: A retrospective study

Schenberg, E. E., de Castro Comis, M. A., Chaves, T. V. et al. · Journal of Psychopharmacology (2014)

A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment

Schenberg, E. E., de Castro Comis, M. A., Alexandre, J. F. M. et al. · Journal of Psychedelic Studies (2017)

35 cited
Treating drug dependence with the aid of ibogaine: a qualitative study

Schenberg, E. E., de Castro Comis, M. A., Alexandre, J. F. M. et al. · Journal of Psychedelic Studies (2016)

Side-effects associated with ketamine use in depression: a systematic review

Short, B., Fong, J., Galvez, V. et al. · Lancet Psychiatry (2017)

From Hofmann to the Haight Ashbury, and into the Future: The Past and Potential of Lysergic Acid Diethlyamide

Smith, D. E., Raswyck, G. E., Dickerson Davidson, L. · Journal of Psychoactive Drugs (2014)

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)

423 cited
50 cited
Psilocybin - Summary of knowledge and new perspectives

Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)

Harm potential of magic mushroom use: A review

Van Amsterdam, J., Opperhuizen, A., Van Den Brink, W. · Regulatory Toxicology and Pharmacology (2011)

169 cited
Safety pharmacology of acute MDMA administration in healthy subjects

Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)

Crystal Structure of an LSD-Bound Human Serotonin Receptor

Wacker, D., Wang, S., Mccorvy, J. D. et al. · Cell (2017)

Ketamine safety and tolerability in clinical trials for treatment-resistant depression

Murrough, J. W., Wan, L., Levitch, C. F. et al. · Journal of Clinical Psychiatry (2015)

Patients’ accounts of increased “Connectedness” and “Acceptance” after psilocybin for treatment-resistant depression

Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)

Potential Psychiatric Uses for MDMA

Yazar-Klosinski, B., Mithoefer, M. C. · Clinical Pharmacology and Therapeutics (2016)

Cited By (41)

Papers in Blossom that reference this study

An international Delphi consensus for reporting of setting in psychedelic clinical trials

Pronovost-Morgan, C., Greenway, K. T., Roseman, L. · Nature Medicine (2025)

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression

Wall, M. B., Demetriou, L., Giribaldi, B. et al. · American Journal of Psychiatry (2025)

Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy

Roseman, L., Erritzoe, D., Nutt, D. J. et al. · JAMA Network Open (2024)

Psychedelic-assisted psychotherapy: Where is the psychotherapy research?

Aday, J. S., Horton, D. M., Fernandes-Osterhold, G. et al. · Psychopharmacology (2024)

Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder

Heinzerling, K. G., Sergi, K., Linton, M. et al. · Frontiers in Psychiatry (2023)

Harnessing placebo: Lessons from psychedelic science

Pronovost-Morgan, C., Hartogsohn, I., Ramaekers, J. G. · Journal of Psychopharmacology (2023)

Show all 41 papers
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors

Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)

Psychedelics and psychological strengths

Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Modlin, N. L., Miller, T. M., Rucker, J. J. et al. · Journal of Affective Disorders (2023)

A Psychoanalytic Perspective on Psychedelic Experience

Guss, J. · Psychoanalytic Dialogues (2022)

Acute and enduring effects of naturalistic psychedelic use among Indigenous peoples in Canada and the United States

de la Salle, S., Gran-Ruaz, S., Davis, A. K. et al. · Canadian Psychology (2022)

8 cited
The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)

Reckweg, J., Uthaug, M. V., Szabo, A. et al. · Journal of Neurochemistry (2022)

Psychedelic medicalization, public discourse, and the morality of ego dissolution

Gearin, A. K., Devenot, N. · International Journal of Cultural Studies (2021)

Ethical and legal issues in psychedelic harm reduction and integration therapy

Pilecki, B., Luoma, J. B., Bathje, G. J. et al. · Harm Reduction Journal (2021)

A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties

Sumner, R. L., Chacko, E., Mcmillan, R. et al. · Journal of Psychopharmacology (2021)

51 cited
The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health

Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)

Post-acute psychological effects of classical serotonergic psychedelics: A systematic review and meta-analysis

Goldberg, S. B., Shechet, B., Nicholas, C. R. et al. · Psychological Medicine (2020)

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

Greenway, K. T., Garel, N., Jerome, L. et al. · Expert Review of Clinical Pharmacology (2020)

Long-term effects of psychedelic drugs: A systematic review

Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)

Self-reported negative outcomes of psilocybin users: A quantitative textual analysis

Bienemann, B., Ruschel, N. S., Campos, M. L. et al. · PLOS ONE (2020)

57 cited
Neuropharmacological modulation of the aberrant bodily self through psychedelics

Ho, J. T., Preller, K. H., Lenggenhager, B. · Neuroscience and Biobehavioral Reviews (2020)

Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory

Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)

DARK Classics in Chemical Neuroscience: Ibogaine

Wasko, M. J., Witt-Enderby, P. A., Surratt, C. K. · ACS Chemical Neuroscience (2018)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Psychedelic-Assisted Psychotherapy: A Paradigm... — Research Summary & Context | Blossom